Line V Hjelle1, Per O M Gundersen2, Jan Oldenburg3, Marianne Brydøy4, Torgrim Tandstad5, Tom Wilsgaard6, Sophie D Fosså7, Roy M Bremnes8, Hege S Haugnes8. 1. Institute of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway Department of Oncology, University Hospital of North Norway, Tromsø, Norway line.v.hjelle@uit.no. 2. Department of Clinical Pharmacology, St. Olav Hospital, University Hospital, Trondheim, Norway. 3. Department of Oncology, Oslo University Hospital, Oslo, Norway. 4. Department of Oncology, Haukeland University Hospital, Bergen, Norway. 5. The Cancer Clinic, St. Olav Hospital, University Hospital, Trondheim, Norway. 6. Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway. 7. Division of Cancer Medicine and Radiotherapy, Rikshospitalet University Hospital, Oslo, Norway Medical Faculty, University of Oslo, Oslo, Norway. 8. Institute of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway Department of Oncology, University Hospital of North Norway, Tromsø, Norway.
Abstract
AIM: Evaluation of long-term platinum (Pt) retention in testicular cancer survivors (TCSs) treated with platinum-based chemotherapy to elucidate possible mechanisms of developing late effects. PATIENTS AND METHODS: 458 TCSs treated 1980-1994 participated in a national follow-up study (2007-2008). Four treatment groups were evaluated for long-term serum Pt levels: surgery (n=135), cumulative cisplatin≤850 mg (n=252), cisplatin>850 mg (n=57) and carboplatin (n=14). RESULTS: The median observation time was 20 (range=13-28) years. The median Pt level according to treatment group was: surgery, 50 ng/l; cisplatin≤850 mg, 85 ng/l; cisplatin>850 mg, 106 ng/l; carboplatin, 40 ng/l. The risk for having a Pt level in the highest quartile was positively associated with cisplatin dose (Ordinal regression (OR)=1.29, per 100 mg increase in cisplatin dose, 95% Confidence interval (CI)=1.20-1.38), and negatively associated with follow-up time (OR=0.50 per 5-year increase in follow-up time, 95% CI=0.37-0.68). CONCLUSION: Pt levels are significantly elevated in serum at a median of 20 years after cisplatin-based chemotherapy for testicular cancer. Copyright
AIM: Evaluation of long-term platinum (Pt) retention in testicular cancer survivors (TCSs) treated with platinum-based chemotherapy to elucidate possible mechanisms of developing late effects. PATIENTS AND METHODS: 458 TCSs treated 1980-1994 participated in a national follow-up study (2007-2008). Four treatment groups were evaluated for long-term serum Pt levels: surgery (n=135), cumulative cisplatin≤850 mg (n=252), cisplatin>850 mg (n=57) and carboplatin (n=14). RESULTS: The median observation time was 20 (range=13-28) years. The median Pt level according to treatment group was: surgery, 50 ng/l; cisplatin≤850 mg, 85 ng/l; cisplatin>850 mg, 106 ng/l; carboplatin, 40 ng/l. The risk for having a Pt level in the highest quartile was positively associated with cisplatin dose (Ordinal regression (OR)=1.29, per 100 mg increase in cisplatin dose, 95% Confidence interval (CI)=1.20-1.38), and negatively associated with follow-up time (OR=0.50 per 5-year increase in follow-up time, 95% CI=0.37-0.68). CONCLUSION:Pt levels are significantly elevated in serum at a median of 20 years after cisplatin-based chemotherapy for testicular cancer. Copyright
Authors: Matthew R Trendowski; Omar El-Charif; Mark J Ratain; Patrick Monahan; Zepeng Mu; Heather E Wheeler; Paul C Dinh; Darren R Feldman; Shirin Ardeshir-Rouhani-Fard; Robert J Hamilton; David J Vaughn; Chunkit Fung; Christian Kollmannsberger; Taisei Mushiroda; Michiaki Kubo; Robyn Hannigan; Frederick Strathmann; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis; M Eileen Dolan Journal: Clin Cancer Res Date: 2019-07-11 Impact factor: 12.531
Authors: Stanley A Yap; Lindsay M Yuh; Christopher P Evans; Marc A Dall'Era; Rebecca M Wagenaar; Rosemary Cress; Primo N Lara Journal: World J Urol Date: 2016-06-15 Impact factor: 4.226
Authors: Andrew M Breglio; Aaron E Rusheen; Eric D Shide; Katharine A Fernandez; Katie K Spielbauer; Katherine M McLachlin; Matthew D Hall; Lauren Amable; Lisa L Cunningham Journal: Nat Commun Date: 2017-11-21 Impact factor: 14.919